Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL and 20 Units per 100 mL of PH Health Limited
Subscribe To Our Newsletter & Stay Updated